Company intelligence / Profile preview

Optima Ovest

Malaga, Western Australia, Australia

Ownership: Private
Development stage: Other

Overview

Optima Ovest manufactures GMP LaNeo™ MDMA capsules for clinical trials and clinical use in Australia, supporting the scale-up of local psychedelic medicine programs.

Therapeutic areas: Psychiatry
Modalities: Small molecule (MDMA and derivatives)
Industry: Contract Manufacturing Organization

Partnerships

Cortexa (joint venture for GMP MDMA supply)PharmAla Biotech (intellectual property, technology transfer partner)Vitura Health

Beyond the preview

Go deeper on Optima Ovest.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optima Ovest.

Explore the full profile